From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 1m 10s
OCUL Stock Faces NDA Catalyst Test
Ocular Therapeutix's Q4 2026 NDA submission could reshape wet AMD treatment if FDA accepts its 505(b)(2) pathway.
In brief
Ocular Therapeutix's Q4 2026 NDA submission could reshape wet AMD treatment if FDA accepts its 505(b)(2) pathway. FDA acceptance of Ocular's NDA by Q4 2026 is critical for stock performance. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
Q2 2026 Earnings Beat
Ocular Therapeutix reported $13.48 million revenue, beating analyst estimates by 5.3%.
AXPAXLI Clinical Breakthrough
AXPAXLI showed 72% less treatment burden for wet AMD patients compared to aflibercept.
NDA Submission Timeline
Ocular plans FDA NDA submission in Q4 2026 after Q3 2026 pre-NDA meeting.
505(b)(2) Pathway Advantage
FDA's 505(b)(2) pathway could speed up review by 60 days using existing safety data.
Q2 2026 Financials
Ocular reported a $0.35 GAAP loss per share, beating estimates by 11.2%.
Cash Runway
Company has $598.6 million cash as of June 30, 2026, sufficient through 2028.
SOL-R Trial Readout
SOL-R Phase 3 trial topline results expected in Q1 2027 to confirm AXPAXLI's efficacy.
Market Competition
Wet AMD market dominated by established anti-VEGF therapies with high cost sensitivity.
Investor Catalyst
Q4 2026 NDA submission is the primary catalyst for stock performance.
Here's the gist
FDA acceptance of Ocular's NDA by Q4 2026 is critical for stock performance.
